Pulmonx Stock

pulmonx.comHealthcareFunding to Date: $226.39MM

Pulmonx is the developer of the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema.

Register for Details

For more details on financing and valuation for Pulmonx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Pulmonx.

Register Today

Team

Management Team

Martin Schneider
Chief Financial Officer, Pulmonx International SARL & Vice President, Finance & Administration
Glendon French
Chief Executive Officer, President & Board Member
Rodney Perkins MD
Founder & Chairman of the Board

Board Members

Charles Chon
Oern Stuge MD
HealthCap
Rodney Perkins MD
Stephen Salmon
Dana Mead Jr.
Kleiner Perkins
Richard Ferrari
De Novo Ventures
Staffan Lindstrand
HealthCap
Glendon French
Michael Matly MD
Montreux Growth Partners
Annette Campbell-White
MedVenture Associates

Other companies like Pulmonx in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$4.26B

News

Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65